Instem achieves a major milestone, acquires all shares of Xybion from Banerjee Group LLC controlled by Dr. Pradip K. Banerjee

BOSTON & STAFFORDSHIRE, England--(BUSINESS WIRE)--Instem today announced the closing of an acquisition of Xybion Digital (“Xybion”). Xybion is best known for its Pristima^TM preclinical study management platform. Like Instem, Xybion has primarily focused on serving life sciences customers, particularly CROs, Pharmas, and Biotechnology firms.

Xybion was founded in 1977 to support preclinical R&D and drug safety testing for regulatory submissions. In 2008, Banerjee Group LLC controlled by veteran life sciences R&D Executive and founding managing partner of Accenture's life sciences R&D business, acquired Xybion and completed further acquisitions of Amadeus solutions, Stelex and Vital Path from GE Healthcare and Autoscribe Informatics.

The core solution, Pristima^TM, is an advanced and cloud-based SaaS study management platform tailored to facilitate primarily GLP preclinical research. Xybion also has solutions in the LIMS space through its Autoscribe^TM brand, for R&D Quality Management (Xybion QMS^TM), and an advisory services arm. Xybion’s software solutions and consulting services serve customers on a global scale, with active customers in over 30 countries across 5 continents.

“The combination of these two companies effectively creates a ‘new Instem’ in the preclinical R&D space – a leader with unparallelled scale and talent enabling us to better focus on our mission to help our customers make discoveries, and to accelerate and advance their research programs. We will also now have more resources to devote to innovation and toward delighting customers. We believe this is a truly transformational development in the field of preclinical life sciences R&D. I also want to take this opportunity to welcome Xybion’s employees to Instem and express how delighted I am that we are joining forces.” Vik Krishnan, CEO, Instem.

The acquisition of Xybion adds many new large and industry-leading customers in the pharmaceutical and CRO spaces.

The combination allows Instem to meet the needs of all life sciences users in preclinical study management. Instem is further supported in its mission with Xybion’s experienced staff in this space. “We are excited about the future after joining forces to solve complex R&D projects in the regulated GLP environment,” further said Mr. Krishnan.

About Instem

Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA and APAC. Instem maintain a commercial and technical presence throughout these regions and pride ourselves on localized support for our diverse client base. Instem has been an ARCHIMED company since 2023.

Learn more about Instem here: www.instem.com